Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Short term Debt (2016 - 2022)

Spero Therapeutics' Short term Debt history spans 5 years, with the latest figure at $141000.0 for Q3 2022.

  • For Q3 2022, Short term Debt changed N/A year-over-year to $141000.0; the TTM value through Sep 2022 reached $141000.0, changed N/A, while the annual FY2018 figure was $223000.0, 0.0% changed from the prior year.
  • Short term Debt reached $141000.0 in Q3 2022 per SPRO's latest filing, up from $115000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $995000.0 in Q1 2022 to a low of $115000.0 in Q2 2022.
  • Average Short term Debt over 3 years is $281200.0, with a median of $223000.0 recorded in 2018.
  • The largest YoY upside for Short term Debt was 2.76% in 2018 against a maximum downside of 0.0% in 2018.
  • A 3-year view of Short term Debt shows it stood at $223000.0 in 2018, then changed by 0.0% to $223000.0 in 2019, then crashed by 36.77% to $141000.0 in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Short term Debt are $141000.0 (Q3 2022), $115000.0 (Q2 2022), and $995000.0 (Q1 2022).